Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial

Journal:

The BMJ

Published:

2026-03-12

DOI:

10.1136/bmj-2025-086115

Affiliations:

26

Authors:

25

Go to article

Institutions	Authors	Share
Fourth Hospital of Hebei Medical University, China	2.000000	0.08
Hengrui, China	2.000000	0.08
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, China	1.000000	0.04
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	1.000000	0.04
Harbin Medical University Cancer Hospital, China	1.000000	0.04
Hubei Cancer Hospital (HBCH), China	1.000000	0.04
Gansu Provincial Cancer Hospital / Gansu Provincial Academic Instiute for Medical Research, China	1.000000	0.04
Shanxi Cancer Hospital, China	1.000000	0.04
Second Affiliated Hospital, AHMU, China	1.000000	0.04
Jilin Province Cancer Hospital, China	1.000000	0.04
Henan Cancer Hospital, ZZU, China	1.000000	0.04
The First Affiliated Hospital, USTC, China	1.000000	0.04
First Affiliated Hospital, ZZU, China	1.000000	0.04
Affiliated Hospital of Chengde Medical University, China	1.000000	0.04
The First Affiliated Hospital, Zhejiang University School of Medicine, China	1.000000	0.04
Shaanxi Traditional Chinese Medicine Hospital, China	1.000000	0.04
First Affiliated Hospital, AHMU, China	1.000000	0.04
The First Affiliated Hospital of Xi'an Jiaotong University, XJTU, China	1.000000	0.04
The Second Affiliated Hospital, Zhejiang University School of Medicine, China	1.000000	0.04
First Affiliated Hospital, GZUCM, China	1.000000	0.04
Fujian Cancer Hospital, China	1.000000	0.04
The First Affiliated Hospital, SYSU, China	1.000000	0.04
The Sixth Affiliated Hospital, SYSU, China	0.500000	0.02
Nanfang Hospital, China	0.500000	0.02

Interested in Oncology and Carcinogenesis?